Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 15 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 15 IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium is the primary intracellular cation, essential for nerve impulse transmission, muscle contraction, and acid-base balance. Replacement therapy with potassium chloride corrects hypokalemia by increasing extracellular potassium concentration, restoring normal membrane potential and cellular function.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion; rate not to exceed 10 mEq/hour (10 mmol/hour) or 0.02 mEq/kg/min (0.02 mmol/kg/min) for adults; maximum concentration 40 mEq/L (40 mmol/L) via peripheral vein; typical dose 20-40 mEq (20-40 mmol) per day.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Terminal half-life: 2-4 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 12-24 hours, increasing risk of hyperkalemia.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Renal: >90% of potassium chloride is excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal/biliary elimination is negligible (<2%) under normal renal function.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."